Home News Stock Analysis: Ebix (NASDAQ: EBIX)

Stock Analysis: Ebix (NASDAQ: EBIX)


Ebix trades as part of the application software industry and trades as part of the technology sector. The company CEO is Robin Raina. Ebix Inc provides software and e-commerce solutions to the insurance, finance and healthcare industries.

Previous Intraday Trading Performance:

The EBIX stock showed a previous change of 0.06% with an open at 63.43 and a close of 63.45. It reached an intraday high of 66.99 and a low of 63.40.

SeekingAlpha:  Ebix: Buy The Dip?


The stock has a market cap of $10.0b with 157.5m shares outstanding, of which the float is 150.0m shares. Trading volume reached 773,277 shares compared to its average volume of 301,856 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Ebix shares returned -15.78% and in the past 30 trading days it returned -19.56%. Over three months, it changed -20.91%. In one year it has changed -4.94% and within that year its 52-week high was 89.10 and its 52-week low was 57.66. EBIX stock is 10.04% above its 52 Week Low.

Our calculations show a 200 day moving average of 78.69 and a 50 day moving average of 77.46. Currently EBIX stock is trading -19.37% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Ebix: Buy The Dip?


The last annual fiscal EPS for the company was reported at 3.17 that ended on 31st of December 2017, which according to the previous close, that is a PE of 20.02. The TTM EPS is 3.35, which comes to a TTM PE of 18.94. Historically, the PE high was 28.10 and the PE low was 4.70. If the stock reached its PE low, that would represent a price of 15.75, which is a decrease of -75.18%.

The following are the last four quarter reported earnings per share:
06-30-2018:  0.92
03-31-2018:  0.83
12-31-2017:  0.84
09-30-2017:  0.76

The dividend per share is currently 0.30, which is a dividend yield of 0.47%. Also, the payout ratio is 8.96%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 64.28, which means it is possibly undervalued and has a margin of safety of 1.28%

Indicators to Watch:

Based on the latest filings, there is 68.30% of institutional ownership. Short-interest is 5,034,473, which is 3.20% of shares outstanding. The short-interest ratio or days-to-cover ratio is 28.16. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 1.49

Business Wire:  Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 22.42%, return on assets is 9.22%, profit margin is 24.52%, price-to-sales is 29.58 and price-to-book is 4.00.

Company Scores:

All scores are out of six:
 3  :Valuation Score
 2  :Past Performance Score
 2  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.